Additionally, Nicholas Prabhakar also reported a case of a CCA patient with BRCA1 and BRCA2 co-pathogenic variants who achieved a 15-month PFS after receiving olaparib treatment (Prabhakar et al., 2024). This evidence concerns the gene BRCA2 and cholangiocarcinoma.